Global Businesses

Urvashi Tyagi

Urvashi Tyagi was appointed Chief Technology Officer in February 2022, responsible for leading the company’s Digital Health Technology team to drive its world-leading cloud-based digital health platforms, as well as investments in emerging technologies including artificial intelligence and machine learning.

Urvashi has over 25 years’ experience in software development and delivery, product strategy, finance, business development, and executive leadership. Before joining ResMed, she was chief technology officer and senior vice president for ADP, responsible for its technology vision and strategy, products modernization, and enterprise technology. She was also the global head of commercial data engineering for American Express, along with senior roles at Amazon’s Audible, Microsoft, and IBM.

Urvashi serves on advisory boards of Worcester Polytechnic Institute (WPI) in Massachusetts and CIONET. She holds a Master’s in information technology from WPI; an MBA in finance and entrepreneurship from South Gujarat University in Surat, India; and a Bachelor’s in mechanical engineering from Sardar Patel University in V.V.Nagar, India.

Lucile Blaise

Lucile Blaise was appointed ResMed’s President of Sleep & Respiratory Care in July 2022, responsible for leading for its core business: providing cloud-connectable devices as well as masks and other accessories to millions of people worldwide living with sleep apnea, COPD, asthma, or other chronic diseases.

Lucile is a medtech industry thought leader with over 25 years’ experience. She was previously ResMed’s Vice President of Sleep & Respiratory Care for Western Europe starting in 2015, where she not only guided the region’s growth strategy, but was instrumental in helping establish public payer market access and reimbursement for telemonitoring in France and Belgium, and telemedicine in France. Before that, she served as Vice President of France and North Africa from 2012 to 2015, and in various ResMed marketing and sales roles within the Sleep & Respiratory Care business going back to 2006.

Lucile is president of the Snitem, France’s premier medtech industry association where she’s served as a board member since 2016. She’s also a board member at MedTech Europe.

Lucile holds a business degree from the KEDGE Business School in Talence, France, and a Bachelor of Arts in international business from the University of Sheffield in England. She speaks four languages: French, English, Spanish, and German.

Bobby Ghoshal

Bobby Ghoshal was appointed President of ResMed’s SaaS business in August 2021, in addition to his role as chief technology officer (CTO), which he’s held since April 2018. He previously served as chief operating officer for Brightree, a ResMed-owned provider of cloud-based software-as-a-service for out-of-hospital care: delivering improved clinical and business performance for homecare customers. Prior to that Bobby led the information technology function for the US, Canada, and Latin America commercial teams, driving adoption of digital platforms and data analytics across the enterprise.

Bobby has more than 25 years’ experience in technology across multiple industries including finance, semiconductors and healthcare, working for companies including Freescale Semiconductor, Motorola, Compuware and Wipro Infotech. Bobby has helped build and lead high-performance teams in information technology, semiconductor innovation, digital and business strategy, information security, advanced analytics, operations and customer care.

Bobby holds a Master of Business Administration degree from Arizona State University and a bachelor’s degree in electronics engineering and telecommunications from the National Institute of Technology (NIT) in Calicut, India.

Justin Leong

Justin Leong was appointed president of ResMed’s Asian and Latin American markets in June 2020, an extension of his role as president of ResMed’s Asia Growth Markets, held since September 2018, and the region’s senior vice president since May 2016. He is also a director on the board of various ResMed subsidiaries. He joined ResMed in 2013 as vice president of Global Strategy, adding the role of General Manager of Greater China in 2015.

Before joining ResMed, Justin was a director at London-based investment firm HgCapital from 2006 to 2012, responsible for acquisitions and portfolio management, and serving on the board of directors of several European healthcare companies. From 1999 to 2004, he was a management consultant with Bain & Co. in Sydney, Boston and New York, where he advised clients on growth strategies, operational improvement projects, mergers and acquisitions.

Justin holds a Bachelor of Commerce and a Bachelor of Laws from the University of New South Wales, Sydney, and a Master of Business Administration from the Harvard Business School.

Katrin Pucknat

Katrin Pucknat was appointed ResMed’s President in Germany in November 2018, leading the umbrella organization ResMed Germany Inc, whose subsidiaries are ResMed Healthcare (ResMed GmbH & Co. KG and ResMed Medizintechnik GmbH) and the specialist trade business of ResMed Deutschland GmbH. Previously, she was CEO of ResMed Healthcare Germany since July 2016, and she has been a member of ResMed’s global management team since 2017.

Katrin has held various European leadership roles in ResMed, dating back to 2010. Previously, she was vice president of EMEA/APAC Business Transformation, responsible for patient service, branch offices, direct sales, and the development of new concepts in ventilation. As director of European Marketing, Sleep & Diagnostics, she was responsible for the sleep-related respiratory disorders business in Europe.

Prior to joining ResMed, Katrin held senior marketing positions in the United States and Europe. She has over 20 years’ experience in the medical device industry with a focus on marketing, communications, business innovation, and business development. She holds a bachelor’s degree in business and marketing.

Andrew Price

Andrew Price was appointed president of ResMed’s global operations in July 2017. He joined ResMed in 1999, most recently serving as president of Innovation and Operations. He also served in a variety of senior leadership roles for the company, including senior vice president of global manufacturing and logistics, vice president of marketing for Asia Pacific, and vice president of product development and marketing in the company’s Sleep-disordered Breathing business unit. He joined ResMed as a design engineer and holds a number of patents granted worldwide.

Prior to joining ResMed, Andrew held product development roles at Sunbeam, a consumer appliances manufacturer, and Aristocrat Leisure Industries, one of the world’s leading providers of gaming solutions.

Andrew graduated from the Advanced Management Program (AMP) at the INSEAD International Business School in Singapore, holds a bachelor’s degree with honors in industrial design from the University of Technology, Sydney, and is a Lean Six Sigma Green Belt.

Brett Sandercock

Brett Sandercock was appointed chief financial officer in January 2006. Previously, he served as ResMed’s vice president of Treasury and Finance from November 2004 until December 2005, and group accountant and controller from 1998 to 2004.

Before joining ResMed, Brett was manager of Financial Accounting and Group Reporting at Norton Abrasives, a division of Saint-Gobain, a French multinational corporation, from 1996 to 1998. He also held finance and accounting roles from 1994 to 1996 at Health Care of Australia, a large private hospital operator. From 1989 to 1994, he worked at Pricewaterhouse Coopers in Sydney, specializing in audits of clients across distribution and manufacturing, financial services, technology, and other industries.

From June 2019 to present, he has served as non-executive chairman of the board of directors of Osteopore Limited (ASX: OSX), an Australian- and Singapore-based medical technology company, commercializing products used for the regeneration of bone across a range of therapeutic areas.

Brett holds a bachelor’s in economics from Macquarie University in Sydney, and is a Certified Chartered Accountant.

Vered Keisar

Vered Keisar was appointed ResMed Chief People Officer in March 2021, responsible for driving the company’s global culture and People strategy. She previously served as vice president and General Counsel for ResMed’s Asia and Latin America regions.

Vered has over 25 years of broad industry experience ranging from healthcare and pharmaceuticals to defense and insurance. Before joining ResMed in 2012, she worked in leading law firms in the UK, Australia, Japan, and Israel.

Vered is qualified to practice law in England and Wales, Australia, and Israel. She has an MBA from the Sydney Graduate School of Management, a Diploma of Laws in European Competition Law from King’s College in London, and a Bachelor of Laws from the College of Management Academic Studies in Israel.

From 2016 to 2020, Vered was the elected chairperson of the Australian Diversity and Inclusion Committee for the Association of Corporate Counsel, the world’s largest organization dedicated to in-house counsel, with more than 45,000 members in 85 countries.

Since 2012, Vered has been an ambassador and speaker for the Australian National Breast Cancer Foundation.

Carlos M. Nunez, M.D.

Carlos M. Nunez, M.D., was appointed ResMed’s chief medical officer in January 2017. Prior to joining ResMed, he was senior vice president of Medical Affairs at Becton, Dickinson and Company, leading the Office of Science, Medicine and Technology for its largest division. Before that, he was chief medical officer at CareFusion, where he built and led a global team that provided company-wide medical oversight.

From 2000 to 2011, Carlos was chief physician executive at Picis, Inc., an industry-leading medical informatics company that became part of the Optum division of UnitedHealth Group. At Picis/Optum, Carlos provided medical leadership and clinical direction for corporate strategy, marketing, product development, sales, implementation and customer relations for global markets.

Before working in the medtech industry, Carlos was a practicing anesthesiologist, intensivist and hospitalist; director of critical care research, informatics and analytics; and the Duke University educational affiliation at Carolinas Medical Center NorthEast.

Carlos received his medical doctorate from the University of Miami School of Medicine, where he also completed his postgraduate training in anesthesiology, critical care medicine and clinical research.

David Pendarvis

David Pendarvis was appointed Chief Administrative Officer and Global General Counsel in May 2011. In addition to those roles, he served as Interim President for ResMed’s EMEA and Japan regions from March to August 2017. He joined ResMed as Global General Counsel in September 2002, and has been Corporate Secretary since February 2003. From 2005 to 2011, he served as senior Vice President of Organisational Development.

Before joining ResMed, David was a partner in the law firm Gray Cary Ware & Freidenrich LLP from 2000 to 2002, where he specialised in intellectual property and general business litigation. From 1986 to 2000, he was a partner at Gibson, Dunn & Crutcher LLP. From 1984 to 1986, he was a law clerk to the Hon. J. Lawrence Irving, US District Judge, Southern District of California.

David was elected to the board of directors of WD-40 Company (NASDAQ: WDFC) in December 2017. He has also served on the board of directors of the San Diego Regional Chamber of Commerce since 2013 and the Corporate Directors Forum since 2010. From 2009 to 2016, he was a director on the board of Sequenom, Inc.

David holds a Bachelor of Arts from Rice University; a Juris Doctor (J.D.), cum laude, from the University of Texas School of Law; a Master of Science in executive leadership from the University of San Diego; and a bachelor’s in political science and managerial studies from Rice University.

Hemanth Reddy

Hemanth Reddy was appointed ResMed’s chief strategy officer in September 2013, responsible for the company’s global corporate strategy and corporate development functions.

Prior to joining ResMed, Hemanth was a strategy consultant for 14 years, advising on a range of issues including corporate strategy, business unit strategy, portfolio strategy, and inorganic growth strategy across consumer products, high tech, biotech and other industries. He was most recently a principal with Monitor Deloitte, Deloitte Consulting’s Strategy practice, co-leading its San Francisco office. Prior to Deloitte, he was a partner with Monitor Group where he co-led corporate finance activities in North America and shared leadership responsibility for Monitor’s Mergers & Acquisitions advisory practice. Before Monitor Group, he was an investment banker with Donaldson, Lufkin & Jenrette (DLJ) in New York, where he advised clients in structuring and executing debt and equity offerings, as well as private equity transactions.

Hemanth holds a Master of Business Administration in Finance, Strategy and Marketing from Northwestern University’s Kellogg School of Management and a bachelor’s in computer science from Cornell University’s College of Engineering.